Vidaza Key To Celgene’s $2.9 Billion Pharmion Purchase
This article was originally published in The Pink Sheet Daily
Executive Summary
Celgene gains first myelodysplastic syndromes therapy to show survival benefit in high-risk patients, as well as full control of multiple myeloma therapy thalidomide and late-stage candidates.
You may also be interested in...
More Satraplatin Pain For GPC As Other Shoe Drops
Celgene backs out of overseas deal for failed prostate-cancer chemo.
More Satraplatin Pain For GPC As Other Shoe Drops
Celgene backs out of overseas deal for failed prostate-cancer chemo.
Celgene Awaits FDA Nod To Relaunch Vidaza With Survival Labeling
Move capitalizes on failure of Eisai’s Dacogen to show a survival benefit in elderly MDS patients.